Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Akums Drugs and Pharmaceuticals Limited ( (IN:AKUMS) ) has shared an announcement.
Akums Drugs and Pharmaceuticals Limited has been granted a patent for its innovative Dual Release Gastro-Resistant Composition, a next-generation proton pump inhibitor (PPI) tablet designed to treat gastroesophageal reflux disease (GERD). This new formulation, which releases medication in two phases, aims to provide extended relief from GERD symptoms, improving patient compliance and quality of life. The development of this advanced, once-daily tablet underscores Akums’ commitment to offering patient-friendly therapies for chronic acid-related disorders, potentially enhancing its market position in the pharmaceutical industry.
More about Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of innovative drug formulations. The company is known for its advanced pharmaceutical products, particularly in the area of gastroenterology, and aims to address prevalent health conditions through cutting-edge therapies.
Average Trading Volume: 12,697
Technical Sentiment Signal: Strong Sell
Current Market Cap: 72.6B INR
See more insights into AKUMS stock on TipRanks’ Stock Analysis page.